Johnson & Johnson has been in the news after announcing plans to separate its Consumer Health segment into a new publicly-traded company, leaving behind a new J&J with its Pharmaceuticals and Medical Device units. The value unlocking potential of this split is real as the company’s Pharmaceutical and Medical Devices units are relatively higher growth, higher-margin businesses but the separation process might take close to 2 years to be fully executed. It is worth mentioning that the company deli ....
24 Nov 2021
Johnson & Johnson - Investment Thesis, Key Drivers, Financial & Price Forecasts, DCF Valuation 11/21
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Johnson & Johnson - Investment Thesis, Key Drivers, Financial & Price Forecasts, DCF Valuation 11/21
Johnson & Johnson (JNJ:NYS), 0 | Johnson & Johnson (0R34:LON), 14,650
- Published:
24 Nov 2021 -
Author:
Ishan Majumdar -
Pages:
14
Johnson & Johnson has been in the news after announcing plans to separate its Consumer Health segment into a new publicly-traded company, leaving behind a new J&J with its Pharmaceuticals and Medical Device units. The value unlocking potential of this split is real as the company’s Pharmaceutical and Medical Devices units are relatively higher growth, higher-margin businesses but the separation process might take close to 2 years to be fully executed. It is worth mentioning that the company deli ....